Risteys ·

Coding

Definition

OMOP Concept ID: 3018081— open in OHDSI Athena.
Part of collection: Beta-2-Microglobulin with 2 other OMOP concepts — open in OHDSI Athena.

OMOP mapping QC

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3018081	u-b2miglo	mg/l (mg/l)	95	144	0.00%
3018081	u-b2miglo	— (—)	9	9	100.00%	Distribution not available

Cohort

Number of people: 105 (49.52% female)

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

No data available for the duration from to last measurement distribution.

Statistics

People with ≥2 records: 15.24%
Median number of measurements per person: 1.0
Median duration from first to last measurement: 2.53 years

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Reference range

N people

N records

0-0.3

—

alle250/kaikki

0-0.3/Kaikki

Value range per person

No data available for the distribution of value range per person.

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Transplanted organ and tissue status

29.04

19.61

1.3

1.8

7.29

6.10

mg/l

—

COPD/asthma related infections

3.82

8.67

1.2

1.4

6.54

11.37

mg/l

0.42

COPD/asthma/ILD related infections

3.82

8.67

1.2

1.4

6.54

11.37

mg/l

0.42

Disorders of amino-acid transport

+∞

5.27

3.4

0.0

27.72

—

mg/l

—

Other viral diseases, including avohilmo

3.30

4.79

2.2

1.5

5.24

12.26

mg/l

0.84

2.40

3.84

1.3

1.4

9.26

8.99

mg/l

0.02

Provisional assignment of new diseases of uncertain etiology

2.81

3.29

1.1

1.3

6.73

10.72

mg/l

0.31

Codes for special purposes

2.81

3.29

1.1

1.3

6.73

10.72

mg/l

0.31

Covid-19 confirmed case

3.17

3.04

1.1

1.2

7.73

11.58

mg/l

0.24

Care involving dialysis

6.01

2.70

3.8

1.1

37.21

5.61

mg/l

—

Other disorders of urethra and urinary system

2.36

2.67

1.7

1.1

13.55

6.97

mg/l

0.51

Dialysis, with operation codes

4.38

2.47

3.6

1.1

31.97

11.99

mg/l

—

ILD medications: azathioprine

6.25

2.37

1.2

1.1

2.02

10.32

mg/l

—

Cerebrovascular diseases (FINNGEN)

3.27

1.83

1.0

8.79

15.42

mg/l

—

Visual disturbances and blindness

2.20

1.83

1.8

1.3

1.54

10.05

mg/l

1.93

Noninfective enteritis and colitis

2.16

1.76

2.1

1.4

13.52

8.05

mg/l

0.29

Persons encountering health services for other counselling and medical advice, not elsewhere classified

1.80

1.63

1.5

1.1

2.59

8.91

mg/l

1.55

Azathioprine

3.57

1.61

1.2

1.5

2.02

6.01

mg/l

—

Follow-up examination after treatment for conditions other than malignant neoplasms

2.56

1.12

1.0

1.5

1.31

21.20

mg/l

—

Open wound of head

1.82

1.07

1.1

1.4

4.72

7.40

mg/l

0.37

Disorders of other endocrine glands

1.87

1.07

2.5

1.4

12.47

9.47

mg/l

0.15

STROKE

1.90

1.05

1.4

1.1

10.49

8.10

mg/l

0.16

Viral infections characterized by skin and mucous membrane lesions

1.85

0.96

2.2

1.3

16.38

9.77

mg/l

—

Insomnia

0.49

0.95

1.7

1.2

16.26

7.76

mg/l

—

Sleep disorders

0.51

0.84

1.7

1.2

16.26

8.39

mg/l

—

Coronary artery bypass grafting

0.00

0.78

0.0

1.0

—

10.08

—

Other diseases of lip and oral mucosa

1.67

0.74

1.3

1.1

6.89

7.83

mg/l

—

Visual disturbances

1.58

0.71

2.0

1.3

0.19

10.43

mg/l

—

Heart failure and bmi 25plus

1.85

0.67

1.0

1.1

11.53

7.40

mg/l

—

Use of hypnotics and sedatives

1.45

0.65

1.3

6.46

7.66

mg/l

0.11

0.00

0.60

0.0

1.2

—

11.44

—

Depression

0.67

0.53

2.4

1.4

7.07

8.99

mg/l

—

Asthma (only as main-diagnosis), excluding more controls

1.47

0.44

1.4

1.1

1.84

12.23

mg/l

—

Asthma (only as main-diagnosis)

1.44

0.43

1.4

1.1

1.84

12.68

mg/l

—

Mood disorders

0.71

0.43

2.3

1.4

6.36

8.99

mg/l

—

Mood [affective] disorders

0.71

0.42

2.3

1.4

6.36

8.99

mg/l

—

Nonischemic cardiomyopathy

0.00

0.41

0.0

1.1

—

8.25

—

Injury of muscle and tendon at hip and thigh level

0.00

0.41

0.0

1.3

—

7.36

—

Premature rupture of membranes

0.00

0.41

0.0

1.5

—

6.52

—

Other diseases of intestine

0.00

0.40

0.0

1.2

—

17.16

—

Haemorrhage in early pregnancy

0.00

0.40

0.0

1.3

—

12.22

—

Insulin, fast-acting (human)

0.00

0.40

0.0

1.4

—

7.05

—

Disorders of ocular muscles, binocular movement, accommodation and refraction

1.42

0.40

3.0

1.4

3.14

10.17

mg/l

—

Spondylopathies

1.36

0.37

1.3

1.1

9.94

8.55

mg/l

0.07

Other disorders of skin and subcutaneous tissue

1.36

0.36

1.5

1.2

6.81

6.80

mg/l

0.00

Other diseases of urinary system

1.29

0.34

1.5

1.2

19.31

6.00

mg/l

1.32

Inflammatory bowel disease

1.36

0.34

1.0

1.2

1.76

9.97

mg/l

—

Asthma/COPD (KELA code 203)

0.75

0.32

1.3

1.5

6.47

8.45

mg/l

—

Behavioural syndromes associated with physiological disturbances and physical factors

0.77

0.28

1.5

1.4

10.24

8.74

mg/l

—

Cystitis

1.27

0.26

1.8

1.1

12.72

6.69

mg/l

0.42

Neurotic, stress-related and somatoform disorders

1.22

0.23

1.3

1.4

3.51

8.98

mg/l

0.72

Diseases of appendix

0.76

0.22

1.1

1.2

1.59

8.33

mg/l

—

Appendicitis, broad definition

0.77

0.22

1.1

1.2

1.59

8.33

mg/l

—

Alzheimer’s disease (Late onset), excluding more controls

0.00

0.22

0.0

1.0

—

4.95

—

Impetigo

0.00

0.21

0.0

1.6

—

5.31

—

Macular hole

0.00

0.21

0.0

1.4

—

5.53

—

Osteomyelitis

0.00

0.21

0.0

1.1

—

1.26

—

Cholangitis (primary sclerosing, PSC)

0.00

0.21

0.0

1.4

—

10.83

—

Left bundle-branch block

0.00

0.21

0.0

1.0

—

15.22

—

Other diseases of biliary tract

0.00

0.21

0.0

1.4

—

5.89

—

Persons encountering health services for specific procedures, not carried out

0.00

0.21

0.0

1.1

—

5.07

—

Other shoulder lesions

0.00

0.21

0.0

1.1

—

0.63

—

Duodenal ulcer

0.00

0.21

0.0

1.0

—

14.31

—

Early lumbar disc prolapse operation

0.00

0.21

0.0

1.4

—

10.50

—

Seronegative rheumatoid arthritis

0.00

0.21

0.0

1.4

—

11.03

—

Other disorders of breast

0.00

0.21

0.0

1.1

—

9.69

—

Benzodiazepine use

1.21

0.21

1.1

1.3

0.65

9.57

mg/l

3.27

Abdominal aortic aneurysm (AAA)

0.00

0.21

0.0

1.4

—

17.09

—

Presbycusis

0.00

0.21

0.0

1.4

—

19.47

—

Hypoglycaemia, other or unspecified

0.00

0.21

0.0

1.4

—

9.13

—

Pilonidal cyst

0.00

0.21

0.0

1.5

—

4.60

—

Prolonged pregnancy

0.00

0.21

0.0

1.5

—

7.69

—

Thiazolidinediones

0.00

0.20

0.0

1.3

—

15.88

—

Disorders of muscles

0.00

0.20

0.0

1.1

—

6.92

—

Peripheral artery operations in Hilmo

0.00

0.20

0.0

1.3

—

13.84

—

Mood disorders, excluding more controls

0.82

0.18

2.3

1.2

6.36

8.92

mg/l

—

Anxiety disorders

1.18

0.18

1.3

1.4

3.51

8.75

mg/l

0.69

Allergic conjunctivitis

0.77

0.15

2.0

1.5

3.65

10.48

mg/l

—

Excessive attrition of teeth

1.16

0.15

1.0

1.4

6.17

10.39

mg/l

—

Asthma, hospital admissions , main diagnosis only

0.83

0.13

1.3

1.5

1.65

9.25

mg/l

—

Caries of enamel

0.87

0.11

1.2

1.3

3.86

7.03

mg/l

0.49

Diseases of external ear

1.11

0.09

1.0

1.3

3.89

9.54

mg/l

—

Anxiety (asthma-related co-morbidities)

1.13

0.07

1.9

1.4

12.98

9.39

mg/l

—

Any mental disorder

0.90

0.07

1.7

1.2

5.04

8.92

mg/l

0.41

Acute appendicitis

0.83

0.07

1.1

1.3

1.59

8.76

mg/l

—

Persons encountering health services in circumstances related to reproduction

1.06

0.07

1.6

15.11

4.98

mg/l

—

All anxiety disorders

1.12

0.06

1.9

1.4

12.98

9.98

mg/l

—

Disorders of eyelid, lacrimal system and orbit

0.88

0.06

1.0

1.2

3.47

6.78

mg/l

—

Psychiatric diseases

0.91

0.05

1.5

1.3

8.61

8.91

mg/l

0.02

Anxiety disorders, excluding more controls

1.08

0.03

1.3

1.2

4.08

9.06

mg/l

0.53

Status epilepticus

0.00

0.0

1.0

—

0.83

—

Disorders of synovium and tendon in diseases classified elsewhere

0.00

0.0

1.0

—

0.87

—

Mandibular prognathia AND surgery (LeFortI or BSSO), including avohilmo

0.00

0.0

2.2

—

9.46

—

Amyloidosis

0.00

0.0

1.0

—

0.24

—

Other/unspecified enthesopathies, not elsewhere classified

0.00

0.0

1.0

—

1.43

—

Other and unspecified hydrocephalus

0.00

0.0

1.8

—

8.04

—

Sicca syndrome [Sjögren]

0.00

0.0

1.5

—

6.40

—

Other symptoms and signs involving the circulatory and respiratory systems

0.00

0.0

1.0

—

0.29

—

Other/unspecified soft tissue disorders related to use, overuse and pressure

0.00

0.0

1.0

—

0.86

—

Atypical facial pain

0.00

0.0

1.7

—

7.97

—

Simple and mucopurulent chronic bronchitis

0.00

0.0

1.2

—

0.93

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Beta-2-Microglobulin [Mass/volume] in Urine

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS